NCT03031730 2026-02-10Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple MyelomaNational Cancer Institute (NCI)Phase 1 Terminated35 enrolled 10 charts
NCT04892264 2025-05-18Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple MyelomaMayo ClinicPhase 1 Terminated5 enrolled
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled